Connelly, Kim A. http://orcid.org/0000-0002-1031-3137
Zhang, Yanling
Desjardins, Jean-François
Nghiem, Linda
Visram, Aylin
Batchu, Sri N.
Yerra, Verra G.
Kabir, Golam
Thai, Kerri
Advani, Andrew
Gilbert, Richard E.
Funding for this research was provided by:
Canada Excellence Research Chairs, Government of Canada
Boehringer Ingelheim
Article History
Received: 11 November 2019
Accepted: 26 January 2020
First Online: 8 February 2020
Ethics approval and consent to participate
: All animal studies were approved by the St Michael’s Hospital Animal Care Committee in accordance with the Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised 1996).
: All authors have reviewed this version of the manuscript and consent to publication.
: KAC has received research grants to his institution from Astra Zeneca and Boehringer Ingelheim, received support for travel to scientific meeting from Boehringer Ingelheim and honoraria for speaking engagements and ad hoc participation in advisory boards from Astra Zeneca, Boehringer Ingelheim and Janssen. REG has received research grants to his institution from Astra Zeneca and Boehringer Ingelheim, received support for travel to scientific meeting from Astra Zeneca and honoraria for speaking engagements and ad hoc participation in advisory boards from Astra Zeneca, Boehringer Ingelheim and Janssen. A.A. has received research support through his institution from AstraZeneca and Boehringer Ingelheim and KC, REG and AA are listed as inventors on a patent application by Boehringer Ingelheim on the use of DPP-4 inhibitors in heart failure.All other authors declare that they have no competing interests.